Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3Phase 3 2Phase 2 2

Status

Completed 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Solid Tumors 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Ovarian Neoplasms 1Leukemia 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Drug Evaluation × Clear all
NCT07532148 2026-04-15

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Chong Kun Dang Pharmaceutical

Phase 1 Not yet recruiting
24 enrolled
Gynecologic

Ovarian Neoplasms

NCT04500587 2024-09-19

Phase 1 First in Human Study of ZN-d5 as a Single Agent

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute

NCT05758610 2024-05-08

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Myeloid, Acute

NCT04840784 2023-10-11

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Terminated
9 enrolled
Other hematologic neoplasm

Leukemia

NCT04972422 2021-09-05

A Phase 1b Study of ZN-c3 in Chinese Subjects

Zentera Therapeutics HK Limited

Phase 1 Unknown
38 enrolled
Other solid neoplasm

Solid Tumors

NCT03236974 2020-02-06

D6090C00002

AstraZeneca

Phase 1 Completed
49 enrolled
Breast

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡